Delving into the Latest Updates on Proflavine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

2,8-Diaminoacridine, Proflavine hemisulfate

Target

DNA

Mechanism

DNA intercalators

Therapeutic Areas

NeoplasmsMouth and Tooth Diseases

Active Indication

Mouth Neoplasms

Inactive Indication

Adenocarcinoma of EsophagusBarrett EsophagusCarcinoma+ [13]

Originator Organization-

Active Organization

National Cancer Institute

Inactive Organization

Icahn School of Medicine at Mount Sinai

National Institutes of Health

Baylor College of Medicine

Drug Highest PhaseEarly Phase 1

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC13H13N3O4S

InChIKeyWSFHCKWLECYVBS-UHFFFAOYSA-N

CAS Registry553-30-0

View All Structures (2)

The investigators have a current trial in China and the US which provides significant support for the safety, cost-effectiveness, accuracy and efficiency of a high resolution microendoscope (HRME)-guided approach in the hands of experienced clinicians. To improve functionality, portability and broader use of this device by non-experts, the investigators recently developed a prototype marHRME platform with an automated, augmented reality (AR)-interpretation that provides an overlaid endoscopic + micro-endoscopic view, facilitating diagnosis and biopsy targeting.

Start Date13 Jan 2022

Sponsor / Collaborator

Rice University

[+2]

NCT02714439 / Active, not recruitingEarly Phase 1IIT

Low-Cost Imaging for Cervical Cancer Prevention in the Texas Lower Rio Grande Valley

The purpose of this study is to evaluate a different type of medical equipment called "High-Resolution Microendoscope" (HRME) for the diagnosis of cervical pre-cancerous lesions and cervical cancer. The investigators want to compare patients' clinical findings using the current equipment used in clinic with the clinical findings using new equipment we are testing on this research project. If the new equipment is proven to give comparable findings with current equipment being used, doctors might be able to offer a diagnosis and treat cervical lesions in one visit. It might not be necessary to wait for cervical biopsies to come back before women would receive the indicated treatment. Study subjects are being asked to participate because they have been diagnosed with an abnormal Papanicolaou (Pap) PAP smear, positive human papillomavirus (HPV) test or history of cervical dysplasia and need to have a colposcopic examination to determine the reason for abnormal results and receive treatment.

Start Date25 Oct 2016

Sponsor / Collaborator

University of Texas Medical Branch

[+3]

NCT02206048 / CompletedNot ApplicableIIT

Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix

The goal of this clinical research study is to learn if it is possible to get high-resolution microendoscopy (HRME) images of AIS tissue and/or tissue from microinvasive carcinoma right before a biopsy of the cervix. Researchers also want to learn if HRME images can show the difference between cancerous tissue and normal cervical tissue.

Start Date02 Oct 2015

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

100 Clinical Results associated with Proflavine

Login to view more data

100 Translational Medicine associated with Proflavine

Login to view more data

100 Patents (Medical) associated with Proflavine

Login to view more data

811

Literatures (Medical) associated with Proflavine

01 Nov 2024·Photochemistry and Photobiology

Test method for evaluating the photocytotoxic potential of fluorescence imaging products

Article

Author: Frankle, Lucas ; Vig, Shruti ; Huang, Huang‐Chiao ; Pfefer, T. Joshua ; Chen, Yu ; Gaitan, Brandon ; Elespuru, Rosalie

AbstractVarious fluorescence imaging agents are currently under clinical studies. Despite significant benefits, phototoxicity is a barrier to the clinical translation of fluorophores. Current regulatory guidelines on medication‐based phototoxicity focus on skin effects during sun exposure. However, with systemic and local administration of fluorophores and targeted illumination, there is now possibility of photochemical damage to deeper tissues during intraoperative imaging procedures. Hence, independent knowledge regarding phototoxicity is required to facilitate the development of fluorescence imaging products. Previously, we studied a cell‐free assay for initial screening of reactive molecular species generation from fluorophores. The current work addresses a safety test method based on cell viability as an adjunct and a comparator with the cell‐free assay. Our goal is to modify and implement an approach based on the in vitro 3T3 neutral red uptake assay of the Organization for Economic Co‐Operation and Development Test Guideline 432 (OECD TG432) to evaluate the photocytotoxicity of clinically relevant fluorophores. These included indocyanine green (ICG), proflavine, methylene blue (MB), and IRDye800, as well as control photosensitizers, benzoporphyrin derivative (BPD) and rose bengal (RB). We performed measurements at agent concentrations and illumination parameters used for clinic imaging. Our results aligned with prior studies, indicating photocytotoxicity in RB and BPD and an absence of reactivity for ICG and IRDye800. DNA interactive agents, proflavine and MB, exhibited drug/light dose–response curves like photosensitizers. This study provides evidence and insights into practices useful for testing the photochemical safety of fluorescence imaging products.

01 Nov 2024·Photochemistry and Photobiology

Shades of phototoxicity in fluorescent imaging agents (that are not supposed to be phototoxic)

Author: Greer, Alexander ; Essang, Serah

AbstractThis article is a highlight of the paper by Huang et al. in this issue of Photochemistry and Photobiology. It describes shades of phototoxicity in fluorescent imaging agents that are not intended to be phototoxic. Phototoxicity was assessed using a modified neutral red uptake (NRU) in vitro assay with mean photo‐effects (MPE) for the fluorescent agents IRdye800, indocyanine green (ICG), proflavine, and methylene blue (MB), with comparisons to known phototoxic agents benzoporphyrin derivative (BPD) and rose bengal (RB). The experimental conditions were aimed to mimic clinical settings, using not only visible light, but also near‐infrared light for insight to photosafety and deep tissue damage. Molecular mechanisms underlying the phototoxicities were not sought, but IRdye800 and ICG were mainly deemed to be safe, whereas proflavine and MB would require precautions since phototoxicity can overshadow their utility as fluorescent imaging agents.

21 May 2024·Journal of Biomedical Optics

Use of topical methylene blue to image nuclear morphometry with a low-cost scanning darkfield microendoscope

Article

Author: Carns, Jennifer ; Richards-Kortum, Rebecca R. ; Anandasabapathy, Sharmila ; Hou, Huayu ; Schwarz, Richard A. ; Gillenwater, Ann M.

SignificanceFiber-optic microendoscopy is a promising approach to noninvasively visualize epithelial nuclear morphometry for early cancer and precancer detection. However, the broader clinical application of this approach is limited by a lack of topical contrast agents available for in vivo use.AimThe aim of this study was to evaluate the ability to image nuclear morphometry in vivo with a novel fiber-optic microendoscope used together with topical application of methylene blue (MB), a dye with FDA approval for use in chromoendoscopy in the gastrointestinal tract.ApproachThe low-cost, high-resolution microendoscope implements scanning darkfield imaging without complex optomechanical components by leveraging programmable illumination and the rolling shutter of the image sensor. We validate the integration of our system and MB staining for visualizing epithelial cell nuclei by performing ex vivo imaging on fresh animal specimens and in vivo imaging on healthy volunteers.ResultsThe results indicate that scanning darkfield imaging significantly reduces specular reflection and resolves epithelial nuclei with enhanced image contrast and spatial resolution compared to non-scanning widefield imaging. The image quality of darkfield images with MB staining is comparable to that of fluorescence images with proflavine staining.ConclusionsOur approach enables real-time microscopic evaluation of nuclear patterns and has the potential to be a powerful noninvasive tool for early cancer detection.

100 Deals associated with Proflavine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Proflavine	-	DB01123

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Helicobacter pylori infection	Preclinical	US	Icahn School of Medicine at Mount Sinai	31 Jan 2015
Intestinal Diseases	Preclinical	US	Icahn School of Medicine at Mount Sinai	31 Jan 2015
Squamous Intraepithelial Lesions	Preclinical	US	Icahn School of Medicine at Mount Sinai	31 Jan 2015
Stomach Cancer	Preclinical	US	Icahn School of Medicine at Mount Sinai	31 Jan 2015
Squamous Intraepithelial Lesions	Discovery	US	Icahn School of Medicine at Mount Sinai	31 Jan 2015
Esophageal Squamous Cell Carcinoma	Discovery	CN	Baylor College of Medicine	31 Jan 2014
Esophageal Squamous Cell Carcinoma	Discovery	US	Baylor College of Medicine	31 Jan 2014
Adenocarcinoma of Esophagus	Discovery	US	Baylor College of Medicine	30 Sep 2012
Barrett Esophagus	Discovery	US	Baylor College of Medicine	30 Sep 2012
Endocarditis, Bacterial	Discovery	US	Baylor College of Medicine	30 Sep 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02206048 (CTgov)	Not Applicable	Cervical Adenocarcinoma In Situ	9	High-Resolution Microendoscopy (HRME) Imaging+Proflavine	umzresgpbn(ybymgcbavu) = vmjcixqokf eahennaxvr (civaxiohuk, creadkvhfe - wsjppcxdbk) View more	-	25 Jul 2022